BioSpace News Archive

CRO renews $250,000 commitment to volunteer program, kicks off leadership program

Text the word “EYE” to 56512 to generate a donation from Horizon to Prevent Blindness to fund TED education

HMP, a leading global organizer of healthcare events and education, today announced that it has acquired Provascular GmbH, a German-based company producing cardiovascular education and events.

Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Karen Savage, Vice President and Milford site head, has been appointed to the Board of Directors of the Milford Area Chamber of Commerce (MACC).

Accolade and Humana Inc. (NYSE: HUM) announced today an expansion of their existing partnership that includes a $20 million strategic investment from Humana

HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that multiple abstracts for HTD1801, the company’s lead development candidate currently in two Phase 2 trials for PSC and NAFLD/NASH, will be presented at The Liver Meeting® 2019,

Health Gorilla and Canvas Medical announced a collaboration to enable data exchange capabilities within the Canvas health technology platform.

Respira Therapeutics, a clinical-stage specialty pharmaceutical company developing next-generation cardiopulmonary disease-targeted inhalation products, has regained full worldwide research, development, and licensing rights to the company’s novel inhaled drug-device combination product, RT234,

Soliton, Inc. (NASDAQ: SOLY), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it has entered into definitive agreements with certain institutional and accredited investors to raise aggregate gross proceeds of approximately $6.25 million

Today announced updates of the continued progress with their Phase III AP-013 clinical trial and their “state-of-the-Art” manufacturing facility.